Adjusted associations of survey completion with MH/SU status, training strategy, and level of computer competency.

<p>*Includes participants not assessed (3 df).</p

Distributions of mental health/substance use and demographic characteristics of study participants and nonparticipants.

<p>Distributions of mental health/substance use and demographic characteristics of study participants and nonparticipants.</p

Adjusted effects of enhanced training, by MH/SU status and levels of computer competency.

<p>*Includes participants not assessed (3 df).</p

Prevalences of (a) mental health and (b) substance use conditions among study participants and nonparticipating HIV/AIDS clinic patients.

<p>Prevalences of (a) mental health and (b) substance use conditions among study participants and nonparticipating HIV/AIDS clinic patients.</p

CD4 cell count (raw) plotted against the sum of Stanford scores for nucleoside and non-nucleoside reverse transcriptase inhibitors ( and , respectively).

<p>The upper limit of CD4 ( cells/mL) was truncated to cells/mL (omitting 19 outliers) to emphasize the overall trend. Because the predicted baseline CD4 tended to decline with both and , we combined the scores into a single ordinal variable to facilitate interpretation. The linear model prediction is displayed as a solid line (generated by fitting a smoothing spline to the predicted values with smoothing parameter ), with confidence intervals displayed as dashed lines.</p

Three-dimensional scatterplot of -transformed plasma viral load (pVL) as a function of Stanford scores for NRTI and NNRTIs ( and ).

<p>Overall, higher was associated with higher pVL, while was inversely associated with pVL. The range of pVL () was truncated to emphasize the overall trend (omitting 73 outliers). The linear model prediction is displayed as a wireframe surface (generated by local polynomial regression with smoothing parameter ).</p

Number and percentage prevalence of putatively transmitted surveillance drug resistance mutations (SDRMs) by residue position in antiretroviral (ARV)-naïve sequences.

<p>PI = protease inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor.</p

Coefficient estimates from AIC-selected linear models of baseline and plasma HIV RNA on position-specific SDRMs and demographic and risk factors.

<p>SDRMs are annotated by HXB2 reference residue and position (gene-specific numbering), followed by an ‘X’ to indicate a non-reference residue. Positions 46, 54, and 90 are in protease and all others are in reverse transcriptase. All estimates were averaged over an ensemble of linear models using Akaike weights. Only terms that were statistically significant () are reported here. NS = not significant.</p

Unadjusted and stabilized weight-adjusted linear models of multinomial exposure variables (M184X and (K103X or K219X)) and (D67X and K219X) on plasma HIV RNA and , respectively.

<p>The model intercepts are taken to be by default, <i>i.e.</i>, none of the designated mutations are present; these estimates are unchanged in the adjusted model and are not repeated for clarity of presentation. Significant () effect estimates are bolded.</p

Coefficient estimates from Akaike Information Criterion (AIC)-selected linear models of baseline and plasma HIV RNA on Stanford scores by drug class and demographic and risk factors.

<p>All estimates were averaged over an ensemble of linear models using Akaike weights. Only statistically significant () terms after weighting are reported. Linear effects of factors were estimated relative to the model intercept, <i>i.e.</i>, a hypothetical female white individual. NS = not significant.</p